Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lipoproteins | 5 | 2021 | 907 | 1.850 |
Why?
|
Triglycerides | 6 | 2021 | 2493 | 1.780 |
Why?
|
Peripheral Arterial Disease | 6 | 2021 | 1091 | 1.530 |
Why?
|
Cardiovascular Diseases | 21 | 2021 | 13413 | 1.230 |
Why?
|
Diabetes Mellitus, Type 2 | 24 | 2020 | 10088 | 1.200 |
Why?
|
C-Reactive Protein | 16 | 2020 | 3569 | 1.100 |
Why?
|
Cholesterol, LDL | 6 | 2020 | 2228 | 0.990 |
Why?
|
Hyperhomocysteinemia | 1 | 2021 | 135 | 0.850 |
Why?
|
Hypertriglyceridemia | 2 | 2021 | 271 | 0.800 |
Why?
|
Ankle Brachial Index | 1 | 2020 | 155 | 0.790 |
Why?
|
Natriuretic Peptide, Brain | 4 | 2017 | 1456 | 0.790 |
Why?
|
Peripheral Vascular Diseases | 3 | 2009 | 601 | 0.750 |
Why?
|
Homocysteine | 3 | 2021 | 659 | 0.740 |
Why?
|
Intercellular Adhesion Molecule-1 | 6 | 2020 | 1184 | 0.720 |
Why?
|
Benzoxazoles | 1 | 2018 | 79 | 0.700 |
Why?
|
Butyrates | 1 | 2018 | 168 | 0.690 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2018 | 188 | 0.640 |
Why?
|
Amino Acid Metabolism, Inborn Errors | 1 | 2018 | 248 | 0.630 |
Why?
|
Peptide Fragments | 4 | 2017 | 5167 | 0.560 |
Why?
|
Troponin T | 3 | 2017 | 707 | 0.540 |
Why?
|
Hypolipidemic Agents | 1 | 2019 | 610 | 0.540 |
Why?
|
Inflammation | 9 | 2020 | 9617 | 0.510 |
Why?
|
Incidence | 19 | 2021 | 20496 | 0.510 |
Why?
|
Venous Thromboembolism | 3 | 2021 | 1429 | 0.500 |
Why?
|
Anti-Inflammatory Agents | 3 | 2018 | 1794 | 0.490 |
Why?
|
Hyperinsulinism | 2 | 2006 | 373 | 0.470 |
Why?
|
Anticholesteremic Agents | 2 | 2018 | 958 | 0.460 |
Why?
|
Interleukin-6 | 8 | 2018 | 3105 | 0.460 |
Why?
|
Lipoproteins, VLDL | 4 | 2021 | 222 | 0.450 |
Why?
|
Cholesterol | 1 | 2020 | 2751 | 0.430 |
Why?
|
Eicosapentaenoic Acid | 1 | 2015 | 516 | 0.420 |
Why?
|
Dyslipidemias | 1 | 2018 | 815 | 0.420 |
Why?
|
Adiponectin | 2 | 2019 | 1098 | 0.410 |
Why?
|
Prospective Studies | 25 | 2021 | 49071 | 0.380 |
Why?
|
Atherosclerosis | 3 | 2021 | 2958 | 0.380 |
Why?
|
Diabetes Complications | 4 | 2011 | 1420 | 0.370 |
Why?
|
Metformin | 2 | 2017 | 740 | 0.370 |
Why?
|
Coronary Artery Disease | 5 | 2021 | 6030 | 0.370 |
Why?
|
Risk Factors | 34 | 2021 | 69278 | 0.360 |
Why?
|
Docosahexaenoic Acids | 1 | 2015 | 817 | 0.360 |
Why?
|
Risk Assessment | 17 | 2021 | 23739 | 0.350 |
Why?
|
Insulin | 4 | 2009 | 6521 | 0.340 |
Why?
|
Hypoglycemic Agents | 3 | 2017 | 2592 | 0.330 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 9337 | 0.330 |
Why?
|
Methotrexate | 3 | 2020 | 1677 | 0.320 |
Why?
|
Middle Aged | 52 | 2021 | 216468 | 0.310 |
Why?
|
Coronary Disease | 5 | 2005 | 6221 | 0.310 |
Why?
|
Aspirin | 4 | 2015 | 3142 | 0.290 |
Why?
|
Vitamin E | 3 | 2015 | 856 | 0.280 |
Why?
|
Female | 57 | 2021 | 375459 | 0.270 |
Why?
|
Women's Health | 5 | 2015 | 1882 | 0.260 |
Why?
|
Medicare | 1 | 2020 | 5077 | 0.260 |
Why?
|
Arteriosclerosis | 3 | 2004 | 1250 | 0.250 |
Why?
|
Proinsulin | 1 | 2003 | 122 | 0.250 |
Why?
|
Humans | 70 | 2021 | 686663 | 0.250 |
Why?
|
Case-Control Studies | 13 | 2021 | 21684 | 0.240 |
Why?
|
Dietary Supplements | 1 | 2015 | 2955 | 0.240 |
Why?
|
Apolipoproteins | 2 | 2021 | 293 | 0.240 |
Why?
|
Obesity | 6 | 2019 | 11700 | 0.240 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2004 | 447 | 0.230 |
Why?
|
Interleukin-1beta | 3 | 2018 | 944 | 0.230 |
Why?
|
Chylomicron Remnants | 1 | 2021 | 3 | 0.230 |
Why?
|
Sex Factors | 7 | 2021 | 10926 | 0.230 |
Why?
|
Fibric Acids | 1 | 2021 | 27 | 0.220 |
Why?
|
Antihypertensive Agents | 1 | 2011 | 2006 | 0.220 |
Why?
|
Cohort Studies | 11 | 2020 | 38732 | 0.220 |
Why?
|
Postmenopause | 3 | 2006 | 2371 | 0.210 |
Why?
|
Cholesterol, HDL | 4 | 2020 | 1768 | 0.210 |
Why?
|
Vitamin D | 1 | 2015 | 3064 | 0.210 |
Why?
|
Double-Blind Method | 9 | 2020 | 11866 | 0.210 |
Why?
|
Colchicine | 1 | 2021 | 254 | 0.210 |
Why?
|
Blood Glucose | 6 | 2018 | 6125 | 0.200 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 727 | 0.200 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39737 | 0.200 |
Why?
|
Estrogen Replacement Therapy | 2 | 2005 | 1177 | 0.200 |
Why?
|
Proportional Hazards Models | 7 | 2020 | 12525 | 0.190 |
Why?
|
Lipoproteins, HDL | 3 | 2020 | 622 | 0.190 |
Why?
|
Insulin Resistance | 6 | 2020 | 3808 | 0.190 |
Why?
|
United States | 14 | 2021 | 65579 | 0.180 |
Why?
|
Smoking | 4 | 2015 | 9029 | 0.180 |
Why?
|
Time Factors | 6 | 2021 | 42271 | 0.180 |
Why?
|
Drug Therapy, Combination | 5 | 2018 | 6632 | 0.180 |
Why?
|
Tissue Plasminogen Activator | 2 | 2005 | 1307 | 0.180 |
Why?
|
Aged | 28 | 2021 | 162271 | 0.170 |
Why?
|
Diabetes Mellitus | 4 | 2016 | 4958 | 0.170 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1812 | 0.160 |
Why?
|
Calgranulin B | 2 | 2007 | 86 | 0.160 |
Why?
|
Body Mass Index | 11 | 2020 | 12323 | 0.160 |
Why?
|
Amputation | 1 | 2021 | 791 | 0.150 |
Why?
|
Adipose Tissue | 4 | 2019 | 3232 | 0.150 |
Why?
|
Blood Pressure | 2 | 2011 | 8529 | 0.150 |
Why?
|
Leptin | 2 | 2016 | 1604 | 0.150 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2018 | 550 | 0.150 |
Why?
|
Hypertension | 2 | 2011 | 7941 | 0.150 |
Why?
|
Diet, Mediterranean | 1 | 2020 | 552 | 0.150 |
Why?
|
Secondary Prevention | 1 | 2021 | 1493 | 0.140 |
Why?
|
Acute-Phase Proteins | 1 | 2015 | 268 | 0.130 |
Why?
|
Fasting | 3 | 2006 | 1573 | 0.130 |
Why?
|
Myocardial Infarction | 6 | 2018 | 11266 | 0.130 |
Why?
|
Predictive Value of Tests | 6 | 2015 | 15407 | 0.120 |
Why?
|
Lower Extremity | 1 | 2021 | 1018 | 0.120 |
Why?
|
Male | 26 | 2021 | 352465 | 0.120 |
Why?
|
Heart Atria | 2 | 2008 | 1241 | 0.110 |
Why?
|
Molecular Weight | 2 | 2011 | 2530 | 0.110 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2021 | 1263 | 0.110 |
Why?
|
Research Report | 1 | 2015 | 346 | 0.110 |
Why?
|
Atrial Natriuretic Factor | 1 | 2013 | 392 | 0.110 |
Why?
|
Risk | 3 | 2013 | 9915 | 0.110 |
Why?
|
Lipoprotein(a) | 2 | 2020 | 343 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 3016 | 0.110 |
Why?
|
Lipids | 3 | 2019 | 3131 | 0.110 |
Why?
|
Antirheumatic Agents | 1 | 2020 | 1273 | 0.100 |
Why?
|
Fluorobenzenes | 1 | 2012 | 187 | 0.100 |
Why?
|
Statistics, Nonparametric | 3 | 2018 | 3009 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15296 | 0.100 |
Why?
|
Disease Management | 2 | 2020 | 2586 | 0.100 |
Why?
|
Drug Combinations | 1 | 2015 | 1899 | 0.100 |
Why?
|
Insulin, Long-Acting | 1 | 2009 | 63 | 0.100 |
Why?
|
Placebos | 2 | 2020 | 1791 | 0.100 |
Why?
|
Inpatients | 1 | 2020 | 2050 | 0.100 |
Why?
|
Age Factors | 5 | 2021 | 19295 | 0.100 |
Why?
|
Body Weight | 4 | 2014 | 4804 | 0.090 |
Why?
|
Diastole | 1 | 2011 | 831 | 0.090 |
Why?
|
Systole | 1 | 2011 | 1008 | 0.090 |
Why?
|
Estrogen Receptor beta | 1 | 2009 | 175 | 0.090 |
Why?
|
Immunoassay | 1 | 2012 | 754 | 0.090 |
Why?
|
Polysaccharides | 1 | 2015 | 976 | 0.090 |
Why?
|
Neoplasms | 2 | 2015 | 19538 | 0.090 |
Why?
|
Death, Sudden, Cardiac | 1 | 2016 | 1489 | 0.090 |
Why?
|
Life Style | 3 | 2014 | 3604 | 0.090 |
Why?
|
Calgranulin A | 1 | 2007 | 81 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2009 | 346 | 0.080 |
Why?
|
Forms and Records Control | 1 | 2007 | 168 | 0.080 |
Why?
|
Antioxidants | 1 | 2015 | 1699 | 0.080 |
Why?
|
Atrial Fibrillation | 2 | 2014 | 4038 | 0.080 |
Why?
|
Echocardiography, Doppler | 2 | 2008 | 981 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2011 | 3687 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2012 | 4477 | 0.080 |
Why?
|
Prognosis | 3 | 2021 | 28923 | 0.070 |
Why?
|
Pravastatin | 1 | 2007 | 391 | 0.070 |
Why?
|
Heptanoic Acids | 1 | 2007 | 360 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2015 | 2963 | 0.070 |
Why?
|
Anthropometry | 2 | 2008 | 1456 | 0.070 |
Why?
|
Cardiotonic Agents | 1 | 2008 | 563 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4208 | 0.070 |
Why?
|
Estrogen Receptor alpha | 1 | 2009 | 567 | 0.070 |
Why?
|
Body Size | 1 | 2008 | 475 | 0.070 |
Why?
|
Statistics as Topic | 1 | 2011 | 2483 | 0.070 |
Why?
|
Fibrinogen | 1 | 2008 | 890 | 0.070 |
Why?
|
Waist-Hip Ratio | 1 | 2006 | 530 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2021 | 8070 | 0.070 |
Why?
|
Logistic Models | 5 | 2016 | 13807 | 0.070 |
Why?
|
Odds Ratio | 4 | 2007 | 10108 | 0.060 |
Why?
|
Interferon-gamma | 1 | 2012 | 3263 | 0.060 |
Why?
|
Carotenoids | 1 | 2006 | 611 | 0.060 |
Why?
|
Confidence Intervals | 3 | 2018 | 3057 | 0.060 |
Why?
|
Treatment Outcome | 5 | 2021 | 60991 | 0.060 |
Why?
|
Endocarditis, Bacterial | 1 | 2006 | 423 | 0.060 |
Why?
|
Lipoproteins, LDL | 2 | 2020 | 643 | 0.060 |
Why?
|
Reference Values | 4 | 2016 | 5134 | 0.060 |
Why?
|
Diet | 3 | 2020 | 7351 | 0.060 |
Why?
|
Creatinine | 1 | 2008 | 1844 | 0.060 |
Why?
|
Sulfonamides | 1 | 2012 | 1961 | 0.060 |
Why?
|
Social Class | 1 | 2011 | 1982 | 0.060 |
Why?
|
Lovastatin | 1 | 2002 | 119 | 0.060 |
Why?
|
Patient Selection | 1 | 2015 | 4381 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 17071 | 0.060 |
Why?
|
Genome-Wide Association Study | 2 | 2021 | 11019 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2011 | 6685 | 0.060 |
Why?
|
Diabetic Angiopathies | 1 | 2007 | 861 | 0.060 |
Why?
|
Primary Prevention | 1 | 2008 | 1116 | 0.050 |
Why?
|
Adult | 11 | 2021 | 211400 | 0.050 |
Why?
|
Migraine Disorders | 1 | 2012 | 1486 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 9304 | 0.050 |
Why?
|
Solubility | 1 | 2002 | 1192 | 0.050 |
Why?
|
Pyrroles | 1 | 2007 | 1215 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2008 | 12734 | 0.050 |
Why?
|
Comorbidity | 2 | 2007 | 10648 | 0.050 |
Why?
|
Apolipoprotein B-100 | 1 | 2020 | 167 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9863 | 0.050 |
Why?
|
Pyrimidines | 1 | 2012 | 2909 | 0.050 |
Why?
|
Apolipoprotein A-I | 1 | 2020 | 274 | 0.050 |
Why?
|
Premedication | 1 | 2020 | 275 | 0.050 |
Why?
|
Smoking Cessation | 1 | 2011 | 1966 | 0.050 |
Why?
|
Longitudinal Studies | 2 | 2015 | 13444 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2019 | 59331 | 0.050 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2010 | 3686 | 0.050 |
Why?
|
Antigens | 1 | 2004 | 1496 | 0.050 |
Why?
|
Policy | 1 | 2021 | 262 | 0.050 |
Why?
|
Glucose Intolerance | 1 | 2002 | 581 | 0.050 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2020 | 225 | 0.050 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 12680 | 0.040 |
Why?
|
Quantitative Trait, Heritable | 1 | 2021 | 566 | 0.040 |
Why?
|
Transaminases | 1 | 2018 | 225 | 0.040 |
Why?
|
Patient Compliance | 1 | 2008 | 2763 | 0.040 |
Why?
|
Abdomen | 1 | 2003 | 1128 | 0.040 |
Why?
|
African Americans | 2 | 2019 | 5144 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2003 | 723 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2021 | 9661 | 0.040 |
Why?
|
American Heart Association | 1 | 2021 | 933 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2003 | 1401 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2016 | 13469 | 0.040 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2006 | 1978 | 0.040 |
Why?
|
Blood Platelets | 1 | 2006 | 2446 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 15075 | 0.040 |
Why?
|
Weight Gain | 1 | 2006 | 2168 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2020 | 802 | 0.040 |
Why?
|
Menopause | 1 | 2003 | 1456 | 0.040 |
Why?
|
Echocardiography | 1 | 2008 | 5097 | 0.040 |
Why?
|
Tissue Culture Techniques | 1 | 2016 | 315 | 0.040 |
Why?
|
Acute Coronary Syndrome | 1 | 2007 | 2294 | 0.030 |
Why?
|
Prediabetic State | 1 | 2018 | 438 | 0.030 |
Why?
|
Regression Analysis | 1 | 2003 | 6669 | 0.030 |
Why?
|
Probability | 2 | 2008 | 2508 | 0.030 |
Why?
|
Lipid Metabolism | 1 | 2021 | 1995 | 0.030 |
Why?
|
Quantitative Trait Loci | 1 | 2019 | 1953 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2006 | 7933 | 0.030 |
Why?
|
Thrombosis | 1 | 2004 | 2759 | 0.030 |
Why?
|
Adiposity | 1 | 2020 | 1656 | 0.030 |
Why?
|
Body Height | 2 | 2008 | 1641 | 0.030 |
Why?
|
Lipoproteins, IDL | 1 | 2010 | 24 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2016 | 1761 | 0.030 |
Why?
|
Stroke | 2 | 2018 | 8730 | 0.030 |
Why?
|
Alcohol Drinking | 1 | 2003 | 3861 | 0.020 |
Why?
|
Sweetening Agents | 1 | 2012 | 249 | 0.020 |
Why?
|
Exercise | 1 | 2006 | 5078 | 0.020 |
Why?
|
Inflammation Mediators | 2 | 2011 | 1971 | 0.020 |
Why?
|
Alleles | 1 | 2021 | 7140 | 0.020 |
Why?
|
Cross-Sectional Studies | 3 | 2005 | 21640 | 0.020 |
Why?
|
Body Surface Area | 1 | 2008 | 211 | 0.020 |
Why?
|
Vitamins | 1 | 2015 | 1363 | 0.020 |
Why?
|
Beverages | 1 | 2012 | 708 | 0.020 |
Why?
|
Xanthophylls | 1 | 2006 | 97 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2005 | 6323 | 0.020 |
Why?
|
Lutein | 1 | 2006 | 121 | 0.020 |
Why?
|
Health Care Costs | 1 | 2020 | 3159 | 0.020 |
Why?
|
Disease Progression | 1 | 2002 | 13204 | 0.020 |
Why?
|
Reference Standards | 1 | 2008 | 891 | 0.020 |
Why?
|
beta Carotene | 1 | 2006 | 521 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 11616 | 0.020 |
Why?
|
Bundle-Branch Block | 1 | 2006 | 279 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 4076 | 0.020 |
Why?
|
Educational Status | 1 | 2011 | 2383 | 0.020 |
Why?
|
Stroke Volume | 2 | 2006 | 4070 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2006 | 1039 | 0.020 |
Why?
|
Acute Disease | 2 | 2006 | 7202 | 0.020 |
Why?
|
Adolescent | 4 | 2019 | 84957 | 0.020 |
Why?
|
Income | 1 | 2011 | 1795 | 0.020 |
Why?
|
Hemostasis | 1 | 2005 | 440 | 0.020 |
Why?
|
Lectins, C-Type | 1 | 2006 | 617 | 0.020 |
Why?
|
Megakaryocytes | 1 | 2006 | 511 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8920 | 0.010 |
Why?
|
International Classification of Diseases | 1 | 2007 | 826 | 0.010 |
Why?
|
Haplotypes | 1 | 2009 | 2913 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2006 | 778 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7631 | 0.010 |
Why?
|
Myocardium | 1 | 2015 | 5024 | 0.010 |
Why?
|
Gene Frequency | 1 | 2009 | 3713 | 0.010 |
Why?
|
Pacemaker, Artificial | 1 | 2006 | 774 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16091 | 0.010 |
Why?
|
Random Allocation | 1 | 2006 | 2507 | 0.010 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 924 | 0.010 |
Why?
|
Doxorubicin | 1 | 2006 | 2249 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 5114 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2016 | 16227 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 2007 | 2152 | 0.010 |
Why?
|
Staphylococcal Infections | 1 | 2006 | 1363 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 5835 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 14744 | 0.010 |
Why?
|
Antigens, CD | 1 | 2006 | 4256 | 0.010 |
Why?
|
Mice | 2 | 2016 | 80803 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2006 | 3076 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2012 | 19308 | 0.010 |
Why?
|
Animals | 3 | 2016 | 170849 | 0.010 |
Why?
|
Linear Models | 1 | 2003 | 6088 | 0.010 |
Why?
|
Electrocardiography | 1 | 2006 | 6435 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 56052 | 0.010 |
Why?
|
Survival Rate | 1 | 2007 | 13606 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 13500 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2006 | 8130 | 0.010 |
Why?
|
Child | 2 | 2008 | 71361 | 0.010 |
Why?
|
Apoptosis | 1 | 2006 | 10261 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2006 | 23439 | 0.010 |
Why?
|
Infant | 1 | 2008 | 33918 | 0.000 |
Why?
|
Child, Preschool | 1 | 2008 | 41159 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2008 | 67320 | 0.000 |
Why?
|